Hemostasis Innovation is Here.

HEMOSIL®
PT, APTT AND FIBRINOGEN ASSAYS
GENERAL SCREENING

The confident choice.
Test after test.



Fully automated on the ACL TOP® Family
of Hemostasis Testing Systems

werfen

A complete line of reagents with excellent stability and efficiency

The broad HemosIL assay menu delivers accuracy, reliability and efficiency—including the efficiency of liquid, ready-to-use Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT) reagents.

Standardized across the ACL TOP Family of systems

HemosIL assays are optimized for:

- Sensitivity
- Clinical utility
- Stability
- Automation

Regardless of testing need, HemosIL assays deliver accurate, timely results—time after time.



HemosIL general screening assays

The most comprehensive, fully automated general screening assays

- Liquid, ready-to-use reagents eliminate reconstitution steps for a majority of general screening assays
  - HemosIL ReadiPlasTin®
  - HemosIL SynthASil®, APTT-SP and SynthAFax®*
- PT reagents with moderate and high sensitivity are available in liquid and lyophilized formats
- Two fibrinogen assays with high and low thrombin concentrations

Optimized for peak efficiency

- Liquid, ready-to-use reagents save valuable tech time
- Eliminate workflow interruptions due to reagent reconstitution wait time
- Full automation on ACL TOP Family and ACL TOP Family 50 Series systems enables rapid turnaround
- Excellent onboard stability minimizes waste

Accuracy for improved patient care

- Minimizes risk of errors by reducing manual reagent handling[1,2]
- Recombinant technology enables consistent PT performance

General Screening Assays
PT
ReadiPlasTin
RecombiPlasTin® 2G
PT-Fibrinogen HS Plus
APTT
SynthASil
APTT-SP
SynthAFax*
Fibrinogen
Q.F.A. Thrombin
Fibrinogen-C

Liquid, ready-to-use format.
*Not available in all countries.

Liquid, ready-to-use HemosIL reagents significantly reduce vial reconstitution



Number of vials reconstituted reduced by ~89%**

**Assumes high-volume, routine testing with PT, APTT, D-Dimer, Anti-Xa and Fibrinogen assays.

HEMOSIL PT ASSAYS

ReadiPlasTin • RecombiPlasTin 2G • PT-FIB HS Plus

Consistent performance from the start, now with a liquid, ready-to-use option


HemosIL PT assays exhibit consistent sensitivity lot after lot to enable optimal monitoring of oral vitamin K antagonist therapy and evaluation of the extrinsic coagulation pathway. Highly stable and consistent, HemosIL PT assays include a variety of sources and types of tissue factor for moderate or high sensitivity.

HemosIL ReadiPlasTin and RecombiPlasTin 2G PT assays

- State-of-the-art recombinant tissue factor and synthetic phospholipids for lot-to-lot consistency
- Excellent assay sensitivity with International Sensitivity Index (ISI) of approximately 1.0 for accurate International Normalized Ratio (INR) results*
- Exceptional stability for minimized reagent waste

A new level of confidence and convenience

- > 700 patient samples, representing a variety of clinical conditions, were tested at three clinical sites using both RecombiPlasTin 2G and ReadiPlasTin assays on ACL TOP systems
- ReadiPlasTin demonstrated comparable performance to RecombiPlasTin 2G, with the convenience of a liquid, ready-to-use format



Accurate results for consistent PT monitoring

Reagent	Approx. ISI*	Factor VII Sensitivity	Heparin Insensitivity
ReadiPlasTin	1.0	Excellent	Up to 1.0 U/mL
RecombiPlasTin 2G	1.0	Excellent	Up to 1.0 U/mL
PT-Fibrinogen HS Plus	1.2	Very Good	Up to 0.4 U/mL

*The ISI, a critical measure within INR, reflects the relative sensitivity of the PT reagent in use. The lower the ISI, the more sensitive the reagent, with the most sensitive reagents having an ISI of close to 1.0. Lot-specific ISI values should always be used to calculate INRs.

HEMOSIL APTT ASSAYS

APTT-SP • SynthASil • SynthAFax

Sensitivity and standardization

When it comes to monitoring therapeutic unfractionated heparin (UFH), an APTT assay with excellent sensitivity is critical. HemosIL SynthASil, APTT-SP and SynthAFax are liquid APTT reagents composed of synthetic phospholipids to ensure optimal sensitivity and lot-to-lot consistency. Additionally, HemosIL APTT assays enable screening of the intrinsic coagulation pathway.

- Consistent therapeutic ranges improve heparin dosing and monitoring
- Consistent sensitivity to intrinsic factor levels and Lupus Anticoagulants (LA) ensures accuracy
- Standardized performance for safer and more effective UFH therapy
- Lot-to-lot consistency ensures precision of results and simplifies clinical interpretation
- Liquid, ready-to-use format and excellent onboard stability (up to 10 days) reduce extra effort and waste

APTT applications

- UFH monitoring
- Screening for coagulation factor deficiencies and inhibitors

Excellent sensitivity in UFH monitoring

Reagent	Heparin Sensitivity	Factor Sensitivity	Lupus Sensitivity	Format
APTT-SP	Excellent	Excellent	Excellent	Liquid
SynthAFax*	Very Good	Very Good	Good	Liquid
SynthASil	Excellent	Excellent	Very Good	Liquid



*Not available in all countries.

HEMOSIL FIBRINOGEN ASSAYS

Q.F.A. Thrombin • Fibrinogen-C

Accurate measurement for bleeding-risk assessment

Fibrinogen abnormalities can be quantitative or qualitative in nature. Although inherited fibrinogen deficiencies are rare, acquired defects (e.g., liver disease) are more common. Accurate measurement of the plasma fibrinogen concentration is an important part of bleeding risk assessment in patients with unexplained prolonged PT and/or APTT results.

HemosIL Q.F.A. Thrombin (bovine) and Fibrinogen-C are both Clauss-based assays—the gold standard for measuring fibrinogen activity[3]—to determine quantitative fibrinogen levels in citrated plasma.

Q.F.A. Thrombin

- Clauss-based fibrinogen assay
- Incorporates 100 UNIH/mL thrombin concentration for decreased interference from direct thrombin inhibitors
- 7-day onboard stability on ACL TOP systems
- Excellent linearity range: 35–1,000 mg/dL

Fibrinogen-C

- Clauss-based fibrinogen assay
- Insensitive to heparin ≤1 U/mL
- Excellent linearity range: 35–1,000 mg/dL




Test after test, HemosIL assays offer complete standardization across ACL TOP systems for optimal efficiency.

HemosIL assays offer pathways to efficiency

Solutions throughout the coagulation cascade

Whether Hemostasis testing relates to the intrinsic, extrinsic or common pathway, the comprehensive HemosIL assays offer an automated solution.



Accurate. Stable. Efficient.

*Not available in all countries.

HemosIL general screening assays

HemosIL®

PT Assays

	ReadiPlasTin	RecombiPlasTin 2G	PT-Fibrinogen HS Plus
Part Number	00020301300 (10 mL) 00020301400 (20 mL)	0020002950 (8 mL) 0020003050 (20 mL)	0008469810
Kit Configuration	5 x 0.5 mL Reagent (liq) 5 x 9.5 mL Diluent (liq) 5 x 1 mL Reagent (liq) 5 x 19 mL Diluent (liq)	5 x 8 mL Reagent (lyo) 5 x 8 mL Diluent (liq) 5 x 20 mL Reagent (lyo) 5 x 20 mL Diluent (liq)	5 x 8.5 mL Rabbit Thromboplastin (lyo) 5 x 8.5 mL Buffer (liq)
ISI (approx.)	1.0	1.0	1.2
Tissue Factor	Human Recombinant	Human Recombinant	Rabbit Brain
Phospholipids	Synthetic	Synthetic	Thromboplastin Extract
Onboard Stability*	10 Days	10 Days (20 mL), 4 Days (8 mL)	5 Days
Heparin Insensitivity	<1.0 U/mL	<1.0 U/mL	<0.4 U/mL
Factor VII Sensitivity	Excellent	Excellent	Very Good

APTT Assays

	SynthASil	APTT-SP	SynthAFax
Part Number	0020006800	0020006300	0020007400
Kit Configuration	5 x 10 mL APTT Reagent (liq) 5 x 10 mL Calcium Chloride (liq)	5 x 9 mL APTT Reagent (liq) 5 x 8 mL Calcium Chloride (liq)	5 x 10 mL APTT Reagent (liq) 5 x 10 mL Calcium Chloride (liq)
Activator	Silica	Silica	Ellagic Acid
Phospholipids	Synthetic	Synthetic	Synthetic
Onboard Stability*	10 Days	5 Days	5 Days
Normal Range†	25.1–36.5 seconds	25.4–36.9 seconds	22.4–32.9 seconds
Heparin Sensitivity	Excellent	Excellent	Very Good
Factor Sensitivity	Excellent	Excellent	Very Good
Lupus Sensitivity	Very Good	Excellent	Good

Fibrinogen Assays

	Q.F.A. Thrombin	Fibrinogen-C
Part Number	0020301800 (2 mL) 0020301700 (5 mL)	0020301100 0020003900-XL
Kit Configuration	10 x 2 mL Bovine Thrombin 10 x 5 mL Bovine Thrombin	10 x 2 mL Bovine Thrombin 10 x 5 mL Bovine Thrombin
Onboard Stability*	7 Days	3 Days
Thrombin Concentration	100 UNIH/mL	35 UNIH/mL
Thrombin Inhibitor Resistance	Excellent	Good

*On ACL TOP and ACL TOP Family 50 Series systems. | †Variables may affect clotting times. Each laboratory should determine its own normal range.

References

1. Bonini P, Plebani M, Ceriotti F, Rubboli F. Errors in laboratory medicine. *Clin Chem.* 2002;48(5):691–698.
2. Simundic AM, Lippi G. Preanalytical phase—a continuous challenge for laboratory professionals. *Biochem Med.* 2012;22(2):145–149.
3. Mackie IJ, Kitchen S, Machin SJ, Lowe GDO. Guidelines on fibrinogen assays. *Br J Haematol.* 2003;121:396–404.

werfen.com

For more information, contact your local Werfen sales representative.

ACL, ACL AcuStar, ACL Elite, ACL TOP, HemoCell, HemoHub, HemosIL, ReadiPlasTin, RecombiPlasTin, SynthAFax and SynthASil are trademarks of Instrumentation Laboratory Company and/or one of its subsidiaries or parent companies and may be registered in the United States Patent and Trademark Office and in other jurisdictions. The Werfen logo is a trademark of Werfen and may be registered in the Patent and Trademark Offices of jurisdictions throughout the world. All other product names, company names, marks, logos and symbols are trademarks of their respective owners.

©2022 Instrumentation Laboratory. All rights reserved.

GENSCRN.NA RevD1 01/22

werfen